Literature DB >> 24676600

Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis.

Neda Amini1, Aslam Ejaz, Gaya Spolverato, Yuhree Kim, Joseph M Herman, Timothy M Pawlik.   

Abstract

BACKGROUND AND OBJECTIVES: Data on outcomes after liver-directed therapy for intrahepatic cholangiocarcinoma (ICC) are limited due to the rarity of the disease. We sought to define overall utilization and temporal trends of liver-directed therapy for ICC.
METHODS: We identified 5,388 patients with ICC using the Surveillance Epidemiology and End Results (SEER) database between 1983 and 2010. Patients were characterized based on the type of liver-directed therapy received: surgical resection, ablation therapy, and radiation therapy.
RESULTS: The majority of patients did not undergo liver-directed therapy (n = 4,156, 77.1%). Among those undergoing liver-directed therapy, surgical resection was most commonly performed (n = 672, 54.5%) and its utilization increased threefold over time (P = 0.001). The use of ablation therapy alone was used in 5.2% of patients and increased nearly sixfold over time (P = 0.39) whereas the use of radiation therapy alone decreased by nearly half (P < 0.001). Overall median survival was 10 months. Poor predictors of survival include tumor-based factors such as regional and distant disease, as well as poorly differentiated and large tumors (>5 cm).
CONCLUSION: There was a moderate improvement in overall survival in patients with ICC between 1983 and 2010. The majority of patients with ICC are not undergoing liver-directed therapy. Among those who do undergo liver-directed therapy, the use of ablation therapy and surgery are increasing with nearly three in five patients undergoing resection.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  cholangiocarcinoma; intrahepatic; liver-directed; outcome; population-based

Mesh:

Year:  2014        PMID: 24676600     DOI: 10.1002/jso.23605

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  29 in total

Review 1.  Ablative therapies for intrahepatic cholangiocarcinoma.

Authors:  Junichi Shindoh
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis.

Authors:  Umberto Cillo; Gaya Spolverato; Alessandro Vitale; Aslam Ejaz; Sara Lonardi; David Cosgrove; Timothy M Pawlik
Journal:  World J Surg       Date:  2015-10       Impact factor: 3.352

3.  Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study.

Authors:  Xu-Feng Zhang; Jeffery Chakedis; Fabio Bagante; Eliza W Beal; Yi Lv; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

4.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

5.  Is Surgical Resection Justified for Advanced Intrahepatic Cholangiocarcinoma?

Authors:  Tomoaki Yoh; Etsuro Hatano; Kenya Yamanaka; Takahiro Nishio; Satoru Seo; Kojiro Taura; Kentaro Yasuchika; Hideaki Okajima; Toshimi Kaido; Shinji Uemoto
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

6.  The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma.

Authors:  Amika Moro; Rittal Mehta; Kota Sahara; Diamantis I Tsilimigras; Anghela Z Paredes; Ayesha Farooq; J Madison Hyer; Itaru Endo; Feng Shen; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Olivier Soubrane; Bas G Koerkamp; Kazunari Sasaki; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2020-03-20       Impact factor: 5.344

7.  Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches.

Authors:  Diamantis I Tsilimigras; Kota Sahara; Lu Wu; Dimitrios Moris; Fabio Bagante; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Feng Shen; Olivier Soubrane; B Groot Koerkamp; Amika Moro; Kazunari Sasaki; Federico Aucejo; Xu-Feng Zhang; Ryusei Matsuyama; Itaru Endo; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2020-09-01       Impact factor: 14.766

Review 8.  Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer.

Authors:  Sukanya Roy; Priyanka Banerjee; Burcin Ekser; Kayla Bayless; David Zawieja; Gianfranco Alpini; Shannon S Glaser; Sanjukta Chakraborty
Journal:  Am J Pathol       Date:  2021-09-09       Impact factor: 4.307

9.  Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Gun Ha Kim; Pyeong Hwa Kim; Jin Hyoung Kim; Pyo-Nyun Kim; Hyung Jin Won; Yong Moon Shin; Sang Hyun Choi
Journal:  Eur Radiol       Date:  2021-08-04       Impact factor: 5.315

10.  A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.

Authors:  Yuma Wada; Mitsuo Shimada; Kensuke Yamamura; Takeo Toshima; Jasjit K Banwait; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Hideo Baba; Masaki Mori; Ajay Goel
Journal:  Hepatology       Date:  2021-06-15       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.